NCT00268385 2026-03-18
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
21 trialsNCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT07422363 2026-03-18
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT06934889 2026-03-17
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03896568 2026-03-05
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03911388 2026-02-17
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04216329 2026-01-23
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT04991870 2026-01-23
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02709226 2025-12-31
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT06806228 2025-11-19
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Petrov, Andrey
Phase 1 Suspended
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03107780 2025-11-13
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04555577 2025-10-29
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT02062827 2025-10-02
M032-HSV-1
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT07134842 2025-08-21
WinGlio-ipi
University College, London
Phase 1 Recruiting
NCT06614855 2025-08-06
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT03452930 2025-06-04
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05698524 2025-05-20
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT01430351 2025-05-07
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02186509 2025-04-30
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Phase 1 Completed